Overall, the median time from biopsy to treatment was 35 days, but differed significantly between patients whose diagnosis ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

Can ctDNA-guided therapy stop cancer’s return, sparing patients unnecessary treatment? A new study suggests it might.

Until prospective data are available, researchers recommend that patients with ER-low breast cancer “should be counseled regarding the potential benefit” of adjuvant endocrine therapy.

She's lost 57 pounds through medical weight loss. She's also doing hormone replacement therapy which she says gives her more energy. The Cunningham Clinic offers a healthier way to age.

The National Institute for Health and Care Excellence (NICE) has recommended ribociclib (Kisqali, Novartis) as an adjuvant treatment ... who have had previous endocrine therapy.

Patients with initial nodal metastases and breast pCR on vacuum-assisted biopsy who underwent targeted axillary dissection had axillary pCR. HealthDay News — Omission of breast surgery after ...

Long-Term Changes to Cardiovascular Biomarkers After Hormone Therapy in the Women's Health Initiative Hormone Therapy Clinical Trials. Obstetrics & Gynecology , 2025; 145 (4): 357 DOI: 10.1097/AOG ...

The project may be best known for changing the way hormones are prescribed during menopause, when safety data led study leaders to immediately stop hormone therapy given to its trial volunteers.

including ASCENT-03 for first line mTNBC subjects who are ineligible for PD-L1-based therapy, ASCENT-05 for early-stage TNBC, and the ASCENT-07 study for hormone receptor + human epidermal growth ...